💊
Adakveo
crizanlizumab
Anemia, Doença Falciforme
ℹ️ Revoked
✅
Nenhum alerta ativo
Este medicamento não apresenta escassez contínua, cartas de segurança ou recolhimentos.
Para que serve
Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.
⚠️ Segurança do paciente
No
Página oficial da EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/adakveo